348 related articles for article (PubMed ID: 30628768)
1. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein.
Chen H; Zhao YF; Chen YX; Li YM
ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768
[TBL] [Abstract][Full Text] [Related]
2. Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease.
He S; Wang F; Yung KKL; Zhang S; Qu S
ACS Chem Neurosci; 2021 Apr; 12(7):1061-1071. PubMed ID: 33769791
[TBL] [Abstract][Full Text] [Related]
3. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
Oueslati A; Fournier M; Lashuel HA
Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
[TBL] [Abstract][Full Text] [Related]
4. Semisynthesis and Enzymatic Preparation of Post-translationally Modified α-Synuclein.
Fauvet B; Lashuel HA
Methods Mol Biol; 2016; 1345():3-20. PubMed ID: 26453202
[TBL] [Abstract][Full Text] [Related]
5. Elucidating the Role of Site-Specific Nitration of α-Synuclein in the Pathogenesis of Parkinson's Disease via Protein Semisynthesis and Mutagenesis.
Burai R; Ait-Bouziad N; Chiki A; Lashuel HA
J Am Chem Soc; 2015 Apr; 137(15):5041-52. PubMed ID: 25768729
[TBL] [Abstract][Full Text] [Related]
6. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease.
Yoo H; Lee J; Kim B; Moon H; Jeong H; Lee K; Song WJ; Hur JK; Oh Y
BMB Rep; 2022 Jul; 55(7):323-335. PubMed ID: 35733294
[TBL] [Abstract][Full Text] [Related]
7. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
9. Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein.
Zhang S; Zhu R; Pan B; Xu H; Olufemi MF; Gathagan RJ; Li Y; Zhang L; Zhang J; Xiang W; Kagan EM; Cao X; Yuan C; Kim SJ; Williams CK; Magaki S; Vinters HV; Lashuel HA; Garcia BA; James Petersson E; Trojanowski JQ; Lee VM; Peng C
Nat Neurosci; 2023 Feb; 26(2):213-225. PubMed ID: 36690898
[TBL] [Abstract][Full Text] [Related]
10. Post-translational modification of α-synuclein in Parkinson's disease.
Barrett PJ; Timothy Greenamyre J
Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
[TBL] [Abstract][Full Text] [Related]
11. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
12. Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications.
Vicente Miranda H; Xiang W; de Oliveira RM; Simões T; Pimentel J; Klucken J; Penque D; Outeiro TF
J Neurochem; 2013 Sep; 126(5):673-84. PubMed ID: 23534813
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
Braithwaite SP; Stock JB; Mouradian MM
Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
[TBL] [Abstract][Full Text] [Related]
14. The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson's disease.
Jęśko H; Lenkiewicz AM; Wilkaniec A; Adamczyk A
Acta Neurobiol Exp (Wars); 2019; 79(3):276-289. PubMed ID: 31587020
[TBL] [Abstract][Full Text] [Related]
15. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
Xu S; Chan P
Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders.
Lu Y; Prudent M; Fauvet B; Lashuel HA; Girault HH
ACS Chem Neurosci; 2011 Nov; 2(11):667-75. PubMed ID: 22860160
[TBL] [Abstract][Full Text] [Related]
17. Targeting α-synuclein post-translational modifications in Parkinson's disease.
Canever JB; Soares ES; de Avelar NCP; Cimarosti HI
Behav Brain Res; 2023 Feb; 439():114204. PubMed ID: 36372243
[TBL] [Abstract][Full Text] [Related]
18. O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α-synuclein aggregation.
Ryan P; Xu MM; Davey AK; Kassiou M; Mellick GD; Rudrawar S
Bioorg Chem; 2020 Jan; 94():103389. PubMed ID: 31753312
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions.
Gadhavi J; Patel M; Bhatia D; Gupta S
Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997
[TBL] [Abstract][Full Text] [Related]
20. Investigating the Effects of O-GlcNAc Modifications in Parkinson's Disease Using Semisynthetic α-Synuclein.
Galesic A; Pratt MR
Methods Mol Biol; 2020; 2133():313-326. PubMed ID: 32144674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
